Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 7/20 | 0.63 |
| ▸ | RAB9A | P51151 | 6/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | CASP3 | P42574 | 2/20 | 0.63 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.63 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | METAP2 | P50579 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25224642 | 1.00 | AHR (1.00) | AHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL30395649 | 0.88 | AHR (0.79) | AHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL25210939 | 0.88 | AHR (0.79) | AHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL16627820 | 0.87 | AHR (1.00) | AHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL1397253 | 0.87 | AHR (0.85) | AHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL30237030 | 0.87 | AHR (0.85) | AHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL25204610 | 0.87 | AHR (0.77) | AHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL30395640 | 0.87 | AHR (0.77) | AHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL16627821 | 0.86 | AHR (0.83) | AHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL25239445 | 0.86 | AHR (0.75) | AHRNPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479822-B2 | AHR agonists | ELI LILLY AND COMPANY (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4402128-A1 | AHR AGONISTS | Eli Lilly and Company (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-118215655-A | AHR agonists | 伊莱利利公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2023039275-A1 | AHR AGONISTS | ELI LILLY AND COMPANY (US) | 2023-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479822-B2 | AHR agonists | AHR, ARNT, RORC | AHR 1/4885NPC1 1273/4885RAB9A 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.